Cardiovascular side effects of androgen deprivation therapy in prostate cancer patients with CVD
-
摘要: 前列腺癌是全世界男性最常见的恶性肿瘤之一。目前前列腺癌的治疗方法主要包括手术、放疗、化疗以及内分泌治疗。雄激素剥脱治疗(androgen deprivation therapy，ADT)作为进展期前列腺癌的一线治疗方案，近年来陆续有文献报道其增加了患者死于心血管病的风险。本文拟对ADT方案及它们的心血管不良反应作一综述。Abstract: Prostate cancer is one of the most prevalent malignant tumors in man around the world. Its therapeutic schemes include radical prostatectomy, radiotherapy, chemotherapy and endocrine therapy. Androgen deprivation therapy (ADT) is the first-line adjuvant therapy option for patients with advanced prostate cancer. However, ADT has been reported to be responsible for some cardiovascular deaths in patients. In this article, various ADT options and their corresponding cardiovascular side effects are summarized as follows.
-
-
表 1 ADT药物及其CVD不良反应机制
药物种类 代表 致CVD作用机制 GnRH激动剂 戈舍瑞林 性腺功能减退所致 GnRH抑制剂 地加瑞克 性腺功能减退所致 抗雄激素类 比卡鲁胺氟他胺恩扎鲁胺(第二代) CYP-17抑制剂 阿比特龙 过多盐皮质激素前体生成 
下载: 导出CSV
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3] Mottet N, De Santis M, Briers E, et al. Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard[J]. Eur Urol, 2018, 73(3): 316-321. doi: 10.1016/j.eururo.2017.09.029
[4] Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J, 2019, 40(48): 3889-3897. doi: 10.1093/eurheartj/ehz766
[5] Merriel S, Martins T, Bailey S. Exploring the Causes of Death Among Patients With Metastatic Prostate Cancer-A Changing Landscape[J]. JAMA Netw Open, 2021, 4(8): e2120889. doi: 10.1001/jamanetworkopen.2021.20889
[6] Liang Z, Zhu J, Chen L, et al. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease?A meta-analysis and systematic review[J]. Andrology, 2020, 8(3): 559-574. doi: 10.1111/andr.12731
[7] 徐涛, 王晓峰. 前列腺癌治疗的"范式转变"——雄激素剥夺治疗应关注心血管的损害[J]. 北京大学学报(医学版), 2014, 46(4): 501-50. doi: 10.3969/j.issn.1671-167X.2014.04.001
[8] 杨丁源, 李俊, 邱明星. 醋酸阿比特龙治疗去势抵抗性前列腺癌合并心血管疾病患者的安全性及生活质量评价[J]. 实用医院临床杂志, 2020, 17(3): 188-191. doi: 10.3969/j.issn.1672-6170.2020.03.055
[9] 李世海, 李强, 张卫东, 等. 前列腺癌长期持续内分泌治疗的临床特点及预后因素分析[J]. 临床泌尿外科杂志, 2020, 35(11): 891-896. doi: 10.13201/j.issn.1001-1420.2020.11.010
[10] Lepor H, Shore ND. LHRH Agonists for the Treatment of Prostate Cancer: 2012[J]. Rev Urol, 2012, 14(1-2): 1-12.
[11] Thomsen FB, Sandin F, Garmo H, et al. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study[J]. Eur Urol, 2017, 72(6): 920-928. doi: 10.1016/j.eururo.2017.06.036
[12] Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis[J]. Eur Urol, 2015, 68(3): 386-396. doi: 10.1016/j.eururo.2014.11.039
[13] Haque R, UlcickasYood M, Xu X, et al. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study[J]. Br J Cancer, 2017, 117(8): 1233-1240. doi: 10.1038/bjc.2017.280
[14] O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer[J]. J Clin Oncol, 2015, 33(11): 1243-1251. doi: 10.1200/JCO.2014.59.1792
[15] Margel D, Ber Y, Peer A, et al. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist[J]. Prostate Cancer Prostatic Dis, 2021, 24(1): 177-185. doi: 10.1038/s41391-020-0264-9
[16] Abufaraj M, Iwata T, Kimura S, et al. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials[J]. Eur Urol, 2021, 79(1): 44-53. doi: 10.1016/j.eururo.2020.06.002
[17] Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice[J]. World J Urol, 2021, 39(2): 307-315. doi: 10.1007/s00345-020-03433-3
[18] George G, Garmo H, Scailteux LM, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases[J]. Int J Cancer, 2021, 148(9): 2203-2211. doi: 10.1002/ijc.33397
[19] Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2018, 378(26): 2465-2474. doi: 10.1056/NEJMoa1800536
[20] Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial[J]. J Clin Oncol, 2016, 34(18): 2098-2106. doi: 10.1200/JCO.2015.64.9285
[21] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(5): 424-433. doi: 10.1056/NEJMoa1405095
[22] Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer(TERRAIN): a randomised, double-blind, phase 2 study[J]. Lancet Oncol, 2016, 17(2): 153-163. doi: 10.1016/S1470-2045(15)00518-5
[23] Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial[J]. Eur Urol, 2020, 78(3): 347-357. doi: 10.1016/j.eururo.2020.04.061
[24] Lu-Yao G, Nikita N, Keith SW, et al. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities[J]. Eur Urol, 2020, 77(2): 158-166. doi: 10.1016/j.eururo.2019.07.031
[25] Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol, 2012, 13(10): 983-992. doi: 10.1016/S1470-2045(12)70379-0
[26] Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer[J]. N Engl J Med, 2017, 377(4): 352-360. doi: 10.1056/NEJMoa1704174
[27] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy[J]. N Engl J Med, 2013, 368(2): 138-148. doi: 10.1056/NEJMoa1209096
[28] Donnell A, Judson I, et al. Hormonal impact of the 17 alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate(CB7630) in patients with prostate cancer[J]. Br J Cancer, 2004, 90(12): 2317-2325. doi: 10.1038/sj.bjc.6601879
[29] Lee HY, Chen HL, Teoh JY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses[J]. Prostate Cancer Prostatic Dis, 2021, 24(1): 244-252. doi: 10.1038/s41391-020-00275-3
[30] Verzoni E, Grassi P, Ratta R, et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors[J]. Ther Adv Med Oncol, 2016, 8(5): 323-330. doi: 10.1177/1758834016656493
[31] Jacobs EJ, Newton CC, Stevens VL, et al. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer[J]. J Clin Oncol, 2014, 32(33): 3716-3722. doi: 10.1200/JCO.2013.54.8875
[32] Harrison MR, Jones LW. Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?[J]. Eur Urol, 2014, 65(5): 873-874. doi: 10.1016/j.eururo.2013.11.033
-